| Similar Articles |
|---|
 |
The Motley Fool
January 18, 2012
Sean Williams |
3 Stocks Under $3 That Could Double in 2012 What these stocks lack in share price they make up for in potential.   |
The Motley Fool
August 11, 2011
Sean Williams |
Aeterna Zentaris: Out of Sight, Out of Mind Perifosine, the company's lead cancer drug, hits key milestones. |
The Motley Fool
November 11, 2011
Sean Williams |
Aeterna Zentaris Surprises Again A quarterly profit shocks analysts and me alike. |
The Motley Fool
January 2, 2012
Sean Williams |
2012 Preview: Aeterna Zentaris Let's look ahead and see what will be driving Aeterna's stock price in 2012. |
The Motley Fool
March 9, 2011
Sean Williams |
10 Small Caps to Rule Them All See if junior miner Golden Star Resources has what it takes to dig up profits for your portfolio. |
The Motley Fool
November 28, 2011
Brian Orelli |
Breaking Down a Biotech Press Release Aeterna Zentaris: FDA Grants IND to Investigator at Baylor College of Medicine for Phase 2A Trial with AEZS-130 in Cancer Cachexia. That sure is a mouthful. Let's see if we can break it down. |
The Motley Fool
December 29, 2011
Brian Orelli |
What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies. |
The Motley Fool
December 23, 2011
Selena Maranjian |
3 Biotech Stocks That Had a Bad 2011 It's a volatile business, and these biotechs got the short end of the stick. |
The Motley Fool
December 31, 2011
Brian Orelli |
3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012. |
The Motley Fool
August 30, 2011
Brian Orelli |
Aeterna Zentaris Passes Its Test AEZS-130, its diagnostic test for adult growth hormone deficiency, looks good. |
The Motley Fool
May 19, 2011
Sean Williams |
Aeterna Zentaris Continues to Deliver Positive Results The most important aspect of Aeterna Zentaris' quarterly filing is its partnership with Yakult Honsha in Japan. |
The Motley Fool
November 9, 2010
Travis Hoium |
Golden Star Resources Shares Plunged: What You Need to Know Golden Star Resources shares fell 12% today after the company released third-quarter results and an exploration update. |
The Motley Fool
March 9, 2011
Brian Orelli |
Slicing and Dicing Your Way through Drug Development The drug developer announces that it licensed the Japanese rights to perifosine, its lead cancer drug, to Yakult Honsha. |
The Motley Fool
September 27, 2011
Brian Orelli |
Promising Results, But It's Still Early Aeterna Zentaris' investors got a bit of good news yesterday while they wait for phase 3 data for the company's colorectal cancer drug perifosine. |
The Motley Fool
November 8, 2011
Travis Hoium |
3 Reasons to Short Groupon In just a few days as a public company there has already been a wide-ranging debate about whether Groupon is a long-term business or a fad that has captivated the country. |
The Motley Fool
May 31, 2011
David Williamson |
Roundtable: The World's Best Biotechs Motley Fool analysts choose these as their favorite biotech stocks: Aeterna Zentaris... Seattle Genetics... BioMarin Pharmaceutical... Amarin... |
The Motley Fool
October 6, 2011
Brian Orelli |
Data Published; Back to Waiting Phase 2 data for Aeterna Zentaris and Keryx's perifosine was published, but it's the phase 3 that's important. |
The Motley Fool
January 18, 2012
Brian Orelli |
2 High-Flying Biotechs Face a New Hurdle The next number-one concern for Aeterna Zentaris' and Keryx's investors should be whether the drug passes its clinical trial. |
The Motley Fool
August 10, 2007
Toby Shute |
Wish Upon a Golden Star Golden Star Resources has investors hopeful after raising production guidance for the full year. With two promising, open-pit mine properties in Ghana, the future looks bright for this gold mining company. |
The Motley Fool
July 29, 2011
Brian Orelli |
2 Biotechs, 1 Promising Cancer Drug Perifosine on the home stretch. |
The Motley Fool
January 6, 2012
Brian Orelli |
Don't Read Too Much Into This Partnership While the partnership is not a sign that Roche will buy Aeterna Zentaris, there's no doubt that the development of AEZS-108 makes the biotech a more attractive takeout candidate. |
The Motley Fool
August 15, 2011
Jim Royal |
6 Wild Bets on Biotech Riches The most interesting biotech tickers. |
The Motley Fool
December 6, 2011
Rick Aristotle Munarriz |
2013 Is Closer Than You Think Some prolific stocks are cheaper than you think. |
BusinessWeek
August 16, 2004
Gene G. Marcial |
Profits Loom For AEterna Zentaris The little-known Canadian biopharma has an array of cancer products that could push it to profitability after years of losses. The stock, now at $4.15, could reach $12 in a year. |
The Motley Fool
November 15, 2011
Sean Williams |
8 High-Growth, Cash-Rich Companies for Your Consideration These eight stocks have shown unparalleled growth over the past three years: Acme Packet... Aixtron... Apple... Bridgeport Education... Cirrus Logic... Erie Indemnity... lululemon... SXC Health Solutions... |
The Motley Fool
May 24, 2007
Mike Havrilla |
A New Era at AEterna A strong balance sheet and a pair of promising products underlie optimism for the biopharmaceutical's future prospects. |
The Motley Fool
December 23, 2011
Brian Orelli |
Geron's Hurry-Up-and-Wait Strategy Clinical trials started, now the waiting begins. |
The Motley Fool
December 2, 2010
Owen Thomas |
What Google Knows About Groupon As much as Groupon may know about what works when placing ads with Google, Google always knows more. |
The Motley Fool
November 7, 2011
Sean Williams |
5 Reasons I'm Not Buying Groupon Twist it any way you like: This has "bubble" written all over it. |
The Motley Fool
October 7, 2010
Roger Friedman |
4 Stocks for Your Watchlist On the importance of keeping a watchlist. |
The Motley Fool
November 11, 2011
David Williamson |
Roundtable: 5 Must-Watch Stocks Highlighting companies experts are watching around the office. |
